In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

If you want to know who really controls uniQure N.V. (NASDAQ:QURE), then you'll have to look at the makeup of its share registry. With 66% stake, institutions possess the maximum shares in the company ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

No patients returned to continuous prophylaxis between year three and year four. There were no serious adverse events related to treatment. Price Action: QURE stock is down 5.95% at $15.25 at last ...

There were no serious adverse events related to treatment. Price Action: QURE stock is down 5.95% at $15.25 at last check Friday.

The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $40.00. QURE has been the subject of a number of recent research reports. Royal Bank o ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

uniQure N.V. announced the completion of enrollment for the first cohort of its Phase I/IIa trial for AMT-191, a gene therapy aimed at treating Fabry disease. The Independent Data Monitoring ...